Skip to content
DraconiticResearch
Search Sources API
206,690 studies31 sourcesUpdated 5 min ago

Oncology

5,185 studies511 in 7 days2,486 in 30 days

Filters
Type
Date
Clear

Latest

5,185 studies

  1. Heterogeneous contributions of APOBEC3 deaminases to substitution and indel mutagenesis in lung adenocarcinoma
    Josefine Striepen, Luka Culibrk, Alexandra Dananberg +3
    Cell ReportsPeer-reviewedCC BY 4.0OncologyCrossref
  2. Pharmacological blockade of p65 palmitoylation modulates NF-κB transcriptional activity
    Jianan Zhang, Lu Hu, Le Sun +4
    Cell ReportsPeer-reviewedCC BY-NC-ND 4.0OncologyCrossref
  3. LINC01537 Regulates Malignant Phenotypes and Predicts Prognosis in Breast Cancer, and Its Bioinformatics Analysis.
    Yuetong Guo, Libo Shi
    Journal of biochemical and molecular toxicologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  4. SHERLOC: An interpretable deep learning model for longitudinal circulating tumor DNA data in survival analysis
    A. Mamann, J. Das, H. Benkirane +5
    bioRxiv (Cold Spring Harbor Laboratory)PreprintCC BYFull textOncologyHAL
  5. Systemic immune-inflammation index predicts survival in gastric cancer: a systematic review and meta-analysis
    Ziyi Yu, Xue Liu, Guoliang Hu +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  6. Single-cell and spatial multi-omics for studying cell competition in the tumor microenvironment
    Prakash Balu, Ashna Sureshkumar, Gayathri Devi Sundaramurthy +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  7. Sequencing-informed, patient-specific droplet digital PCR assays for circulating tumor DNA monitoring in recurrent or metastatic head and neck cancer: a pilot study
    Luca Leonardo Amodio, Lea Grossmann, Stefanie Gächter +10
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  8. Intracranial dose constraints in IDH-wildtype glioblastoma: a framework for context-specific application
    Flavio Donnini, Paolo Tini
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  9. The SLC7A11–ferroptosis axis in BRCA1-mutant breast cancer: current mechanistic evidence, potential therapeutic vulnerabilities, and translational perspectives
    Yuying Yang, Yu Li, Xiaoyu Hao +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  10. Risk prediction models for postoperative pneumonia in lung cancer patients: a systematic review and meta-analysis
    Chuansheng Li, Yunxi Jiang, Yanmei Wang
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  11. Readiness for stoma reversal in patients with a diverting stoma: a concept analysis
    Xian Zhou, Wen Xu, Yu Zeng +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  12. Promoter hypomethylation associated with elevated TRIM33 expression in triple-negative breast cancer patients
    Archana Chaudhary, Manish Kumar, Md. Jawed Akhtar +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  13. Information rather than architecture: cross-learner attribution and clinician–model complementarity in CIN2+ risk prediction for women referred for colposcopy
    Yuzhang Wu, Aihong Wang
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  14. Neuron–tumor communication as a target for neuromodulatory drug delivery in cancer
    Muhammad Esa, Tawseef Ahmad, Muhammad Khan +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  15. COL1A2 expression is associated with prognosis, stromal remodeling, and predicted immunotherapy response in gastric cancer
    Fengming Luan, Guofeng Chen, Ke Chen +4
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  16. Grading and prognostic implications of tertiary lymphoid structures and CD155 expression in invasive breast carcinoma
    Wenxin Yang, Yiming Li, Guiming Wang +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  17. Multi-scale convolution with efficient channel attention improves benign–malignant classification of spinal tumors on T2-weighted fat-suppressed MRI
    Zhiwei Ma, Xingyu Duan, Xiaorong Ma +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  18. PD-L1 deletion or blockade intrinsically reduces macrophage CD80 levels
    Trinity Waddell, Haidong Dong, Minna Roh-Johnson +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  19. TMC8 is associated with a paradoxical immune landscape and promotes clear cell renal cell carcinoma progression
    Kuanyin Wang, Xingshu Zhu, Minghui Li +4
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  20. Prognostic significance of SLC25A28 and its associations with mitochondrial metabolism and immune features in glioma
    Wangyang Yu, Yue Yang, Wenli Guo +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  21. A highly successful case report: a patient with intestinal hepatoid adenocarcinoma and liver metastases achieves excellent efficacy following immune-targeted therapy
    Siyu Yu, Zhenjie Dai, Dan Jiang +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  22. Development and validation of a multiphase CT radiomics-based machine learning model for prognostic prediction in sarcomatoid renal cell carcinoma
    Tongpeng Liu, Yu Yao, Zhijian Zhou +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  23. Multimodal CT radiomics and 2.5D deep learning for preoperative grading of clear cell renal cell carcinoma in older patients: a multicenter study
    Zhengkun Wang, Zixin Liang, Dingyang Lv +9
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  24. Risk factors and treatment outcomes of metachronous isolated distant metastasis in oral squamous cell carcinoma: A multicenter retrospective cohort study in Japan
    Yasumasa Kakei, Takumi Hasegawa, Takumi Imai +10
    Oral Oncology ReportsPeer-reviewedCC BYFull textOncologyDOAJ
  25. Normalized administered atezolizumab dose and clinical outcomes in advanced solid tumors: an exploratory analysis of the phase I PCD4989g study.
    V Moreno, M Dorta, A Rueda +5
    Immuno-oncology technologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC